{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:46:28Z","timestamp":1773449188034,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:00:00Z","timestamp":1616198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:00:00Z","timestamp":1616198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s10067-021-05697-5","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T19:02:26Z","timestamp":1616266946000},"page":"3783-3788","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Tuberculosis despite latent infection screening and treatment in patients receiving TNF inhibitor therapy"],"prefix":"10.1007","volume":"40","author":[{"given":"Yagmur","family":"Kaptan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asli","family":"Suner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Nedim","family":"Ta\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahrettin","family":"Oksel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenan","family":"Aksu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6788-9727","authenticated-orcid":false,"given":"Abdullah","family":"Sayiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,20]]},"reference":[{"key":"5697_CR1","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1097\/00007890-199911150-00009","volume":"68","author":"A Sayiner","year":"1999","unstructured":"Sayiner A, Ece T, Duman S, Yildiz A, Ozkahya M, Kili\u00e7aslan Z, Tokat Y (1999) Tuberculosis in renal transplant recipients. Transplantation 68:1268\u20131271","journal-title":"Transplantation"},{"key":"5697_CR2","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1086\/506935","volume":"43","author":"P Brassard","year":"2006","unstructured":"Brassard P, Kezouh A, Suissa S (2006) Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 43:717\u2013722","journal-title":"Clin Infect Dis"},{"key":"5697_CR3","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1136\/annrheumdis-2013-204960","volume":"74","author":"EV Arkema","year":"2015","unstructured":"Arkema EV, Jonsson J, Baecklund E, Bruchfeld J, Feltelius N, Askling J, on behalf of the ARTIS Study Group (2015) Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments. Ann Rheum Dis 74:1212\u20131217","journal-title":"Ann Rheum Dis"},{"key":"5697_CR4","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1086\/383317","volume":"38","author":"RS Wallis","year":"2004","unstructured":"Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38:1261\u20131265","journal-title":"Clin Infect Dis"},{"key":"5697_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","volume":"15","author":"S Minozzi","year":"2016","unstructured":"Minozzi S, Bonovas S, Lytras T, Pecoraro V, Gonzalez-Lorenzo M, Bastiampillai AJ, Gabrielli EM, Lonati AC, Moja L, Cinquini M, Marino V, Matucci A, Milano GM, Tocci G, Scarpa R, Goletti D, Cantini F (2016) Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis and ankylozing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf 15:11\u201334","journal-title":"Expert Opin Drug Saf"},{"key":"5697_CR6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jmii.2013.03.005","volume":"47","author":"X Xie","year":"2014","unstructured":"Xie X, Li F, Chen JW, Wang J (2014) Risk of tuberculosis infection in anti-TNF-alpha biological therapy: From bench to bedside. J Microbiol Immunol Infect 47:268\u2013274","journal-title":"J Microbiol Immunol Infect"},{"key":"5697_CR7","unstructured":"Turkish Ministry of Health, Department of Public Health (2019) Guidelines for the diagnosis and treatment of tuberculosis (in Turkish). https:\/\/hsgm.saglik.gov.tr\/depo\/birimler\/tuberkuloz_db\/haberler\/Tuberkuloz_Tani_Ve_Tedavi_Rehberi_\/Tuberkuloz_Tani_ve_Tedavi_Rehberi_08.07.2019_Yuksek_KB.pdf. Accessed 18 December 2020"},{"key":"5697_CR8","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/thx.2005.046797","volume":"60","author":"British Thoracic Society Standards of Care Committee","year":"2005","unstructured":"British Thoracic Society Standards of Care Committee (2005) BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to anti-TNF-alpha treatment. Thorax 60:800\u2013805","journal-title":"Thorax"},{"key":"5697_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000434684","volume":"90","author":"S Borekci","year":"2015","unstructured":"Borekci S, Atahan E, Yilmaz DD, Maz\u0131can N, Duman B, Ozguler Y, M\u00fcsellim B, Hamuryudan V, Ongen G (2015) Factors affecting the tuberculosis risk in patients receiving anti-tumor necrossi factor-alpha treatment. Respiration 90:191\u2013198","journal-title":"Respiration"},{"key":"5697_CR10","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1111\/crj.12726","volume":"12","author":"T Cagatay","year":"2018","unstructured":"Cagatay T, Bingol Z, K\u0131yan E, Yegin Z, Okumus G, Arseven O, Erkan F, G\u00fclbaran Z, Erelel M, Ece T, Cagatay P, K\u0131l\u0131caslan Z (2018) Follow-up of 1887 patients receiving tumor necrosis factor-alpha antagonists: tuberculin skin test conversion and tuberculosis risk. Clin Respir J 12:1668\u20131675","journal-title":"Clin Respir J"},{"key":"5697_CR11","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/ijd.12628","volume":"54","author":"T Ergun","year":"2015","unstructured":"Ergun T, Seckin D, Bulbul EB, Onsun N, Ozgen Z, Unalan P, Alpsoy E, Karakurt S (2015) The risk of tuberculosis in patients with psoriasis treated with anti-tumor necrosis factor agents. Int J Dermatol 54:594\u2013599","journal-title":"Int J Dermatol"},{"key":"5697_CR12","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1002\/art.11137","volume":"48","author":"JJ Gomez-Reino","year":"2003","unstructured":"Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, on behalf of the BIOBADASER Group (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. Arthritis Rheum 48:2122\u20132127","journal-title":"Arthritis Rheum"},{"key":"5697_CR13","doi-asserted-by":"publisher","first-page":"428","DOI":"10.5588\/ijtld.13.0644","volume":"18","author":"YJ Jung","year":"2014","unstructured":"Jung YJ, Lee JY, Jo KW, Yoo B, Lee CK, Kim YG, Yang SK, Byeon JS, K\u0130m KJ, Ye BD, Lee KH, Lee SD, Kim WS, Kim DS, Shim TS (2014) The \u201ceither test positive\u201d strategy for latent tuberculous infection before anti-tumour necrosis factor treatment. Int J Tuberc Lung Dis 18:428\u2013434","journal-title":"Int J Tuberc Lung Dis"},{"key":"5697_CR14","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3109\/00365548.2014.938691","volume":"46","author":"HC Kim","year":"2014","unstructured":"Kim HC, Jo KW, Jung YJ, Yoo B, Lee CK, Kim YG, Yang SK, Byeon JS, Kim KJ, Ye BD, Shim TS (2014) Diagnosis of latent tuberculosis infection before initiation of anti-tumour necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold in Tube assay. Scand J Infect Dis 46:763\u2013769","journal-title":"Scand J Infect Dis"},{"key":"5697_CR15","doi-asserted-by":"publisher","first-page":"905","DOI":"10.5588\/ijtld.13.0755","volume":"18","author":"KR Bonfiglioli","year":"2014","unstructured":"Bonfiglioli KR, Ribeiro AC, Moraes JC, Saad CG, Souza FH, Calich AL, Bonfa E, Laurindo IM (2014) LTBI screening in rheumatoid arthritis patients prior to anti-TNF treatment in an endemic area. Int J Tuberc Lung Dis 18:905\u2013911","journal-title":"Int J Tuberc Lung Dis"},{"key":"5697_CR16","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.crohns.2013.11.008","volume":"8","author":"C Debeuckelaere","year":"2014","unstructured":"Debeuckelaere C, De Munter P, Van Bleyenbergh P, De Wever W, Van Assche G, Rutgeerts P, Vermeire S (2014) Tuberculosis infection following anti-TNF therapy in inflammatory bowel disease, despite negative screening. J Crohns Colitis 8:550\u2013557","journal-title":"J Crohns Colitis"},{"key":"5697_CR17","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s10067-008-0867-3","volume":"27","author":"I Hanta","year":"2008","unstructured":"Hanta I, Ozbek S, Kuleci S, Kocabas A (2008) The evaluation of latent tuberculosis in rheumatologic diseases for anti-TNF therapy: experience with 192 patients. Clin Rheumatol 27:1083\u20131086","journal-title":"Clin Rheumatol"},{"key":"5697_CR18","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1097\/MEG.0000000000001403","volume":"31","author":"F Akyuz","year":"2019","unstructured":"Akyuz F, Cavus B, Iliaz R, Soyer OM, Ormeci A, Evirgen S, Onder S, Koksalan K, Keskin M, Karaca C, Demir K, Gulluoglu M, Cagatay T, Besisik F, Kaymakoglu S (2019) Inflammatory bowel disease and mycobacteria: how much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy ? Eur J Gastroenterol Hepatol 31:777\u2013780","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"5697_CR19","first-page":"282","volume":"13","author":"N Busquets-Perez","year":"2017","unstructured":"Busquets-Perez N, Ponce A, Ortiz-Santamaria V, de Agustin de Oro J, Hernandez-Rico YL, Vidal I, Alfonso C, Argemi S, Munoz B, Quispe F, Diaz AC, Campos S, Hernandez TM, Torres M, Suris X (2017) How many patients with rheumatic diseases and TNF inhibitors treatment have latent tuberculosis. Rheumatol Clin 13:282\u2013286","journal-title":"Rheumatol Clin"},{"key":"5697_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/cid\/ciu796","volume":"60","author":"L Munoz","year":"2015","unstructured":"Munoz L, Casa S, Juanola X, Bordas X, Martinez C, Santin M, for the Prevention of Anti-TNF-Associated Tuberculosis Study Team of Bellvitge University Hospital (2015) Prevention of anti-tumor necrosis factor-associated tuberculosis: a 10-year longitudinal cohort study. Clin Infect Dis 60:349\u2013356","journal-title":"Clin Infect Dis"},{"key":"5697_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.5152\/eurasianjmed.2020.19226","volume":"52","author":"PY Gulhan","year":"2020","unstructured":"Gulhan PY, Elverisli MF, Ercelik M, Aytekin M, Balbay O, Arbak P (2020) Relationship between diagnosis period and internal and external air quality in patients with tuberculosis. Eurasian J Med 52:77\u201380","journal-title":"Eurasian J Med"},{"key":"5697_CR22","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jiph.2016.11.003","volume":"10","author":"E Ceylan","year":"2017","unstructured":"Ceylan E, Karkucak M, Coban H, Karadag M, Yakut T (2017) Evaluation of TNF-alpha gene (G308A) and MBL2 gene codon 54 polymorphisms in Turkish Patients with tuberculosis. J Infect Public Health 10:774\u2013777","journal-title":"J Infect Public Health"},{"key":"5697_CR23","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/bjd.12544","volume":"169","author":"I Sauzullo","year":"2013","unstructured":"Sauzullo I, Mengoni F, Marocco R, Potenza C, Skroza N, Tieghi T, Lichtner M, Vullo V, Mastroianni CM (2013) Interferon-gamma release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonistis: in vivo and in vitro analysis. Br J Dermatol 169:1133\u20131140","journal-title":"Br J Dermatol"},{"key":"5697_CR24","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1093\/ecco-jcc\/jjy057","volume":"12","author":"CK Lee","year":"2018","unstructured":"Lee CK, Wong SHV, Lui G, Tang W, Tam LS, Ip M, Hung E, Chen M, Wu JC, Ng SC (2018) A prospective study to monitor for tuberculosis during anti-tumour necrosis factor therapy in patients with inflammatory bowel disease and immune-mediated inflammatory diseases. J Crohns Colitis 12:954\u2013962","journal-title":"J Crohns Colitis"},{"key":"5697_CR25","doi-asserted-by":"publisher","first-page":"518","DOI":"10.5588\/ijtld.17.0650","volume":"22","author":"JE Stout","year":"2018","unstructured":"Stout JE, Belknap R, Wu YJ, Ho CS (2018) Paradox of serial interferon-gamma release assays: variability width more important than specificity size. Int J Tuberc Lung Dis 22:518\u2013523","journal-title":"Int J Tuberc Lung Dis"},{"key":"5697_CR26","first-page":"E322","volume":"41","author":"I Bastian","year":"2017","unstructured":"Bastian I, Coulter C, the National Tuberculosis Advisory Committee (NTAC) (2017) Position statement on interferon-gamma release assays for the detection of latent tuberculosis infection. Commun Dis Intell Q Rep 41:E322\u2013E336","journal-title":"Commun Dis Intell Q Rep"},{"key":"5697_CR27","first-page":"1127","volume":"10","author":"L Sichletidis","year":"2006","unstructured":"Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D (2006) Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 10:1127\u20131132","journal-title":"Int J Tuberc Lung Dis"},{"key":"5697_CR28","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3899\/jrheum.150177","volume":"43","author":"B Kisacik","year":"2016","unstructured":"Kisacik B, Pamuk ON, Onat AM, Erer SB, Hatemi G, Ozguler Y, Pehlivan Y, Kilic L, Ertenli I, Can M, Direskeneli H, Keser G, Oksel F, Dalkilic E, Yilmaz S, Pay S, Balkarli A, Cobankara V, Cetin GY, Sayarlioglu M, Cefle A, Yazici A, Avci AB, Terzioglu E, Ozbek S, Akar S, Gul A (2016) Characteristics predicting tuberculosis risk under tumor-necrosis factor-alpha inhibitors: report from a large multicenter cohort with high background prevalence. J Rheumatol 43:524\u2013529","journal-title":"J Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05697-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05697-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05697-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T09:12:41Z","timestamp":1628673161000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05697-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,20]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["5697"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05697-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,20]]},"assertion":[{"value":"27 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarat\u0131ons"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The study was approved by the Ethics Committee of Ege University Faculty of Medicine (approval no: 18-10\/23) and was therefore performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. The patients gave informed consent for their clinical data to be used in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All tuberculosis patients gave written informed consent to participate in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors attest to the validity of the data and give consent to their publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}